Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorBerinstein, Jeffrey

About this trial

The goal of this trial is to create personalized treatments for each patient admitted to the hospital with acute severe ulcerative colitis (ASUC). The study will test the feasibility and acceptability of these treatment strategies among patients and physicians so that the study team can later do a larger trial to test whether the medication treatment pathways help patients avoid colectomy while ensuring patient's are safe.

Eligibility criteria

Qualifiers

Patient ≥ 18 to 75 years of age at baseline

Diagnosis of ulcerative colitis (verified by a typical clinical history as well as characteristic appearance on endoscopy and histology)

Current hospital admission for ulcerative colitis treatment (expecting IV corticosteroid initiation)

Temperature > 37.5C

Disqualifiers

Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease

On IV corticosteroids for ≥ 72 hours prior to enrollment continuously (at any institution)

Currently pregnant or breastfeeding

Patients who meet diagnostic criteria for toxic megacolon during this current admission. This will be determined by the study team and inpatient treatment team according to the following supportive criteria: Having dilation of the colon > 6m and three of the following (Temperature>38C, HR >120 BPM, WBC>10500/µL, Hemoglobin < 10.5mg/dL) and one of the following (dehydration, altered mental status, severe electrolyte disturbances, and hypotension)

Trial design

Treatments tested in this trial

  • Cyclosporine Injection (IV)
  • Cyclosporine Oral Product
  • Upadacitinib Extended Release Oral Tablet
  • Intravenous Methylprednisolone
  • Prednisone Oral Product

Treatment groups

162 Participants
are divided into 9 treatment groups

9

Treatment groups

See each treatment group below.

Sponsors and collaborators

Berinstein, Jeffrey

Lead sponsor

University of Michigan

Sponsor institution

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator